TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biosynex SA ( (FR:ALBIO) ) has provided an update.
BIOSYNEX SA announced the number of shares and voting rights as of February 28, 2025, with 18,748,031 shares and 22,531,235 voting rights. This information reflects the company’s current capital structure and may impact shareholder decisions and market perception, reinforcing BIOSYNEX’s transparency and regulatory compliance.
More about Biosynex SA
BIOSYNEX, founded in 2005, is a French laboratory specializing in health diagnostics, particularly in rapid tests, biotherapy monitoring, and molecular biology. The company focuses on innovative health solutions for laboratories, hospitals, doctors, and the general public, enhancing patient care. BIOSYNEX expanded internationally post-Covid-19, with subsidiaries in the US, Europe, and Asia, and offers a wide range of products through its BIOSYNEX PHARMACY and BIOSYNEX DIAGNOSTIC divisions.
YTD Price Performance: 33.02%
Average Trading Volume: 344
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €26.99M
For an in-depth examination of ALBIO stock, go to TipRanks’ Stock Analysis page.